MGMT Status as a Clinical Biomarker in Glioblastoma.
Biomarkers, Tumor
/ genetics
Brain Neoplasms
/ drug therapy
Clinical Decision-Making
/ methods
DNA Methylation
DNA Mismatch Repair
DNA Modification Methylases
/ genetics
DNA Repair Enzymes
/ genetics
Drug Resistance, Neoplasm
/ genetics
Gene Expression Profiling
Gene Expression Regulation, Neoplastic
Glioblastoma
/ drug therapy
Humans
Predictive Value of Tests
Prognosis
Progression-Free Survival
Promoter Regions, Genetic
/ genetics
Temozolomide
/ pharmacology
Tumor Suppressor Proteins
/ genetics
MGMT
biomarker
glioblastoma
neuro-oncology
precision medicine
Journal
Trends in cancer
ISSN: 2405-8025
Titre abrégé: Trends Cancer
Pays: United States
ID NLM: 101665956
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
30
09
2019
revised:
07
02
2020
accepted:
13
02
2020
entrez:
30
4
2020
pubmed:
30
4
2020
medline:
12
6
2021
Statut:
ppublish
Résumé
Glioblastoma is the most common primary malignant brain tumor. Although current standard therapy extends median survival to ~15 months, most patients do not have a sustained response to treatment. While O
Identifiants
pubmed: 32348734
pii: S2405-8033(20)30070-4
doi: 10.1016/j.trecan.2020.02.010
pmc: PMC7315323
mid: NIHMS1580168
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Tumor Suppressor Proteins
0
DNA Modification Methylases
EC 2.1.1.-
MGMT protein, human
EC 2.1.1.63
DNA Repair Enzymes
EC 6.5.1.-
Temozolomide
YF1K15M17Y
Types de publication
Journal Article
Research Support, N.I.H., Intramural
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
380-391Subventions
Organisme : Intramural NIH HHS
ID : Z01 BC006150
Pays : United States
Informations de copyright
Published by Elsevier Inc.
Références
Acta Neuropathol. 2012 Oct;124(4):547-60
pubmed: 22810491
Clinics (Sao Paulo). 2011;66(10):1747-55
pubmed: 22012047
Int J Cancer. 2008 Mar 15;122(6):1391-9
pubmed: 18000822
Arch Med Res. 2013 May;44(4):281-90
pubmed: 23608672
Oncologist. 2017 Apr;22(4):432-437
pubmed: 28275120
JAMA Oncol. 2017 Jun 1;3(6):784-792
pubmed: 28097324
J Cancer Res Clin Oncol. 2012 Nov;138(11):1789-97
pubmed: 22986811
N Engl J Med. 2008 Jul 31;359(5):492-507
pubmed: 18669428
Clin Cancer Res. 2019 Mar 15;25(6):1809-1816
pubmed: 30514777
Cancer Res. 2017 Jan 1;77(1):198-206
pubmed: 27793847
Neuropathol Appl Neurobiol. 2018 Feb;44(2):172-184
pubmed: 28574607
BMC Cancer. 2011 Jan 26;11:35
pubmed: 21269507
Pathol Res Pract. 2017 Dec;213(12):1489-1493
pubmed: 29103769
J Neurooncol. 2010 May;97(3):311-22
pubmed: 19841865
Nat Rev Neurol. 2014 Jul;10(7):372-85
pubmed: 24912512
Neuro Oncol. 2009 Aug;11(4):348-56
pubmed: 19224763
Mutat Res Rev Mutat Res. 2016 Jul-Sep;769:19-35
pubmed: 27543314
N Engl J Med. 2005 Mar 10;352(10):997-1003
pubmed: 15758010
Cancer Chemother Pharmacol. 2009 Sep;64(4):647-55
pubmed: 19543728
Int J Cancer. 2011 Aug 1;129(3):659-70
pubmed: 21425258
Neuro Oncol. 2019 Feb 14;21(2):167-178
pubmed: 30189035
Clin Cancer Res. 2019 Mar 15;25(6):1828-1837
pubmed: 30514778
Acta Neuropathol Commun. 2019 Jun 5;7(1):89
pubmed: 31167648
Appl Immunohistochem Mol Morphol. 2017 Aug;25(7):497-504
pubmed: 27153440
Int J Oncol. 2015 Aug;47(2):417-28
pubmed: 26035292
Neurosurgery. 2009 Nov;65(5):866-75; discussion 875
pubmed: 19834398
J Clin Oncol. 2009 Dec 1;27(34):5743-50
pubmed: 19805672
J Transl Med. 2012 Dec 17;10:250
pubmed: 23245659
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Int J Clin Oncol. 2010 Aug;15(4):352-8
pubmed: 20232102
Br J Cancer. 2009 Jul 7;101(1):124-31
pubmed: 19536096
Neuro Oncol. 2014 Sep;16(9):1263-73
pubmed: 24510240
PLoS One. 2011 Feb 18;6(2):e17156
pubmed: 21365007
Neuro Oncol. 2009 Jun;11(3):281-91
pubmed: 18952979
Cancer Res. 2015 Aug 1;75(15):3127-38
pubmed: 26025730
J Neurooncol. 2016 Jun;128(2):333-9
pubmed: 27029617
J Biol Chem. 1996 Jun 7;271(23):13916-24
pubmed: 8662860
Biochim Biophys Acta. 2012 Aug;1826(1):71-82
pubmed: 22244911
Acta Neuropathol. 2011 May;121(5):651-61
pubmed: 21287394
Curr Neurol Neurosci Rep. 2015 Jan;15(1):507
pubmed: 25394859
Brain Pathol. 2008 Oct;18(4):520-32
pubmed: 18400046
Neuro Oncol. 2013 Mar;15(3):370-81
pubmed: 23328811
Cancer Res. 2017 Feb 15;77(4):823-826
pubmed: 28159862
Clin Transl Oncol. 2016 Apr;18(4):391-7
pubmed: 26289551
Biochim Biophys Acta. 2011 Dec;1816(2):179-90
pubmed: 21745538
Jpn J Clin Oncol. 2007 Dec;37(12):897-906
pubmed: 18156172
Onco Targets Ther. 2013 Sep 27;6:1363-72
pubmed: 24109190
iScience. 2018 Dec 21;10:247-264
pubmed: 30553813
Sci Rep. 2018 Apr 30;8(1):6704
pubmed: 29712977
J Clin Oncol. 2008 Sep 1;26(25):4189-99
pubmed: 18757334
Tumour Biol. 2016 Jan;37(1):87-96
pubmed: 26518768
J Neurooncol. 2015 May;122(3):441-50
pubmed: 25682093
Int J Cancer. 2010 Nov 1;127(9):2106-18
pubmed: 20131314
Nat Rev Neurol. 2010 Jan;6(1):39-51
pubmed: 19997073
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Mol Cancer Ther. 2014 May;13(5):1334-44
pubmed: 24568970
Neurology. 2013 Oct 22;81(17):1515-22
pubmed: 24068788
PLoS One. 2011 Jan 07;6(1):e16146
pubmed: 21249131